Your browser doesn't support javascript.
loading
PET-based radiomics signature can predict durable responses to CAR T-cell therapy in patients with large B-cell lymphoma.
Ligero, Marta; Simó, Marc; Carpio, Cecilia; Iacoboni, Gloria; Balaguer-Montero, Maria; Navarro, Victor; Sánchez-Salinas, Mario Andres; Bobillo, Sabela; Marín-Niebla, Ana; Iraola-Truchuelo, Josu; Abrisqueta, Pau; Sala-Llonch, Roser; Bosch, Francesc; Perez-Lopez, Raquel; Barba, Pere.
Affiliation
  • Ligero M; Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona Spain.
  • Simó M; Nuclear Medicine Department Vall d'Hebron University Hospital, Autonomous University of Barcelona Barcelona Spain.
  • Carpio C; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Iacoboni G; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Balaguer-Montero M; Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona Spain.
  • Navarro V; Oncology Data Science (ODysSey) Group Vall d'Hebron Institute of Oncology (VHIO) Barcelona Spain.
  • Sánchez-Salinas MA; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Bobillo S; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Marín-Niebla A; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Iraola-Truchuelo J; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Abrisqueta P; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Sala-Llonch R; Faculty of Medicine Department of Biomedicine Institute of Neurosciences, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) University of Barcelona Barcelona Spain.
  • Bosch F; Centro de Investigación Biomédica en Red de Bioingeniería Biomateriales y Nanomedicina (CIBER-BBN) Barcelona Spain.
  • Perez-Lopez R; Department of Hematology Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Barcelona Barcelona Spain.
  • Barba P; Radiomics Group Vall d'Hebron Institute of Oncology (VHIO) Vall d'Hebron Barcelona Hospital Campus (VHUH) Barcelona Spain.
EJHaem ; 4(4): 1081-1088, 2023 Nov.
Article in En | MEDLINE | ID: mdl-38024636
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: EJHaem Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: EJHaem Year: 2023 Document type: Article